US5206366A
(en)
*
|
1992-08-26 |
1993-04-27 |
Pfizer Inc. |
Process for preparing aryl piperazinyl-heterocyclic compounds
|
ES2083319B1
(es)
*
|
1993-09-20 |
1997-01-16 |
Pfizer |
Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
|
EP0790236B1
(en)
*
|
1996-02-13 |
2003-11-19 |
Pfizer Inc. |
Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
|
TW491847B
(en)
*
|
1996-05-07 |
2002-06-21 |
Pfizer |
Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
KR100333214B1
(ko)
*
|
1996-05-07 |
2002-06-20 |
디. 제이. 우드, 스피겔 알렌 제이 |
5-(2-(4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐)에틸)-6-클로로-1,3-디하이드로-2(1에이치)인돌-2-온(지프라시돈)의메실레이트트리하이드레이트염,이의제조방법및도파민디2길항물질로서의이의용도
|
IL127497A
(en)
*
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
US6150366A
(en)
*
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US7030142B1
(en)
*
|
1999-04-06 |
2006-04-18 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
|
SI1181018T1
(en)
*
|
1999-05-27 |
2003-06-30 |
Pfizer Products Inc. |
Ziprasidone suspension
|
US7175855B1
(en)
*
|
1999-05-27 |
2007-02-13 |
Pfizer Inc. |
Ziprasidone suspension
|
FR2802101B1
(fr)
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
PE20011061A1
(es)
|
2000-02-01 |
2001-11-20 |
Procter & Gamble |
Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
|
US6562974B2
(en)
|
2000-02-01 |
2003-05-13 |
The Procter & Gamble Company |
Process for making geminal bisphosphonates
|
US20040023951A1
(en)
*
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
ATE503845T1
(de)
*
|
2001-12-10 |
2011-04-15 |
Novartis Pharma Gmbh |
Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
|
UY27668A1
(es)
*
|
2002-02-20 |
2003-10-31 |
Pfizer Prod Inc |
Composición de ziprasidona y controles sintéticos
|
US20040048876A1
(en)
*
|
2002-02-20 |
2004-03-11 |
Pfizer Inc. |
Ziprasidone composition and synthetic controls
|
EP3173082A1
(en)
*
|
2002-05-17 |
2017-05-31 |
Duke University |
Method for treating obesity
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
ES2297200T3
(es)
*
|
2002-10-24 |
2008-05-01 |
Pfizer Products Inc. |
Derivados de acilo de 5-(2-(4-(1,2 bencisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona que presentan actividad neuroleptica.
|
WO2004050655A1
(en)
*
|
2002-12-04 |
2004-06-17 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of ziprasidone and its hydrochloride
|
US7488729B2
(en)
|
2002-12-04 |
2009-02-10 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
|
CN1255105C
(zh)
*
|
2002-12-17 |
2006-05-10 |
上海医药工业研究院 |
齐拉西酮及其盐的水溶性包合物及其制备方法
|
US20050143396A1
(en)
*
|
2003-04-11 |
2005-06-30 |
Hertero Drugs Limited |
Novel crystalline forms of ziprasidone hydrochloride
|
SI2316456T1
(sl)
*
|
2003-04-29 |
2017-10-30 |
Orexigen Therapeutics, Inc. |
Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
|
AU2004237951A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
|
EP1530570A2
(en)
*
|
2003-06-03 |
2005-05-18 |
Teva Pharmaceutical Industries Limited |
CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
|
US20050049295A1
(en)
*
|
2003-06-12 |
2005-03-03 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
|
US7667037B2
(en)
*
|
2003-10-24 |
2010-02-23 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparation of ziprasidone
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
AU2003285600A1
(en)
*
|
2003-11-28 |
2005-06-24 |
Siddiqui Mohammed Jaweed Mukarram |
Process for the preparing ziprasidone monohydrochloride hydrate
|
CA2550485A1
(en)
*
|
2003-12-18 |
2005-07-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form b2 of ziprasidone base
|
WO2005065660A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Alpharma, Inc. |
Ziprasidone formulations
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
AU2005206139B2
(en)
*
|
2004-01-13 |
2009-02-26 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
WO2005085240A2
(en)
*
|
2004-02-27 |
2005-09-15 |
Ranbaxy Laboratories Limited |
Process for the preparation of ziprasidone
|
WO2005100348A1
(en)
*
|
2004-04-15 |
2005-10-27 |
Lupin Limited |
Amorphous ziprasidone hydrochloride
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
CN1968692A
(zh)
*
|
2004-05-03 |
2007-05-23 |
杜克大学 |
影响体重减轻的组合物
|
EP1744750A2
(en)
*
|
2004-05-06 |
2007-01-24 |
Sandoz AG |
Pharmaceutical composition comprising hydrophobic drug having improved solubility
|
ITMI20040944A1
(it)
*
|
2004-05-11 |
2004-08-11 |
Dinamite Dipharma S P A In For |
Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
|
CA2467538C
(en)
*
|
2004-05-14 |
2010-08-24 |
Apotex Pharmachem Inc. |
New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
|
US20070237828A1
(en)
*
|
2004-06-11 |
2007-10-11 |
Dr. Reddy's Laboratories Limited |
Ziprasidone Dosage Form
|
CA2471219A1
(en)
*
|
2004-06-14 |
2005-12-14 |
Apotex Pharmachem Inc. |
Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
MX2007002309A
(es)
*
|
2004-08-24 |
2007-10-08 |
Johnson & Johnson |
Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
|
WO2006026426A2
(en)
*
|
2004-08-27 |
2006-03-09 |
University Of Kentucky Research Foundation |
Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
|
US7777037B2
(en)
*
|
2004-10-27 |
2010-08-17 |
Dr. Reddy's Laboratories Limited |
Ziprasidone process
|
CA2487003C
(en)
*
|
2004-11-05 |
2012-03-13 |
Apotex Pharmachem Inc. |
Process for the preparation of ziprasidone (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one)
|
WO2006086779A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Teva Pharmaceutical Industries Ltd. |
Amorphous ziprasidone mesylate
|
CA2500667C
(en)
*
|
2005-03-11 |
2013-01-15 |
Apotex Pharmachem Inc. |
Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
|
WO2006099452A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Anhydrous ziprasidone mesylate and a process for its preparation
|
CA2599391A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ziprasidone mesylate
|
MX2007013026A
(es)
*
|
2005-04-22 |
2008-01-11 |
Wyeth Corp |
Combinaciones terapeuticas para el tratamiento o prevencion de trastornos psicoticos.
|
JP2008545650A
(ja)
*
|
2005-05-20 |
2008-12-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
スルファミド誘導体の製造方法
|
CN101370488B
(zh)
*
|
2005-11-22 |
2012-07-18 |
奥雷西根治疗公司 |
增加胰岛素敏感性的组合物
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8716231B2
(en)
*
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US20070155824A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
|
US8492431B2
(en)
*
|
2005-12-19 |
2013-07-23 |
Janssen Pharmaceutica, N.V. |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191460A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
|
US20070191451A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
HU230479B1
(hu)
*
|
2006-05-02 |
2016-07-28 |
Richter Gedeon Nyrt. |
Eljárás 5-{2-[4-(1,2-benzizotiazol-3-il)-1-piperazinil]-etil}-6-klór-1,3-dihidro-2H-indol-2-on (Ziprasidon) előállítására
|
EP2026790A2
(en)
*
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
EP2041304B1
(en)
|
2006-06-12 |
2011-09-07 |
Hadasit Medical Research Services & Development Limited |
Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
|
KR101735466B1
(ko)
|
2006-11-09 |
2017-05-15 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
KR20090090316A
(ko)
*
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
HUP0600868A3
(en)
*
|
2006-11-24 |
2009-03-30 |
Richter Gedeon Nyrt |
5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
|
EP2146577A1
(en)
*
|
2007-05-18 |
2010-01-27 |
Scidose, Llc |
Ziprasidone formulations
|
EP2197446A4
(en)
*
|
2007-08-31 |
2012-01-25 |
Reddys Lab Ltd Dr |
PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
|
WO2009116085A2
(en)
*
|
2008-03-11 |
2009-09-24 |
Alkem Laboratories Ltd. |
An improved process for the preparation of ziprasidone
|
US20090247616A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
JP2011521973A
(ja)
*
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
EA018567B1
(ru)
|
2008-06-23 |
2013-08-30 |
Янссен Фармацевтика Нв |
Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
WO2010073255A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Cadila Healthcare Limited |
Process for preparing ziprasidone
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
CA2798172C
(en)
|
2010-01-07 |
2017-11-21 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
BR112012016783A2
(pt)
|
2010-01-11 |
2015-09-01 |
Orexigen Therapeutics Inc |
"usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
|
CN102234272A
(zh)
*
|
2010-04-21 |
2011-11-09 |
上海医药工业研究院 |
盐酸齐拉西酮半水合物的制备方法
|
WO2011148253A2
(en)
|
2010-05-25 |
2011-12-01 |
Aurobindo Pharma Limited |
Solid dosage forms of antipsychotics
|
PL391810A1
(pl)
|
2010-07-14 |
2012-01-16 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Nowe sole ziprasidonu oraz sposoby ich otrzymywania
|
WO2012020424A1
(en)
|
2010-08-12 |
2012-02-16 |
Arch Pharmalabs Limited |
A short process for the preparation of ziprasidone and intermediates thereof
|
PL2608670T3
(pl)
|
2010-08-23 |
2019-05-31 |
Alkermes Pharma Ireland Ltd |
Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
|
DK3034079T3
(en)
|
2010-11-15 |
2018-02-05 |
Agenebio Inc |
PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
|
SI23610A
(sl)
|
2011-01-13 |
2012-07-31 |
Diagen@d@o@o |
Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
|
AU2013271622B2
(en)
|
2012-06-06 |
2018-03-01 |
Nalpropion Pharmaceuticals Llc |
Methods of treating overweight and obesity
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
MX2016007808A
(es)
|
2013-12-20 |
2016-09-07 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
|
MX2020013374A
(es)
|
2015-06-19 |
2022-05-06 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
|
US20170323239A1
(en)
|
2016-05-06 |
2017-11-09 |
General Electric Company |
Constrained time computing control system to simulate and optimize aircraft operations with dynamic thermodynamic state and asset utilization attainment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112020026062B1
(pt)
|
2018-06-19 |
2023-04-04 |
Agenebio, Inc |
Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
|
US20240132513A1
(en)
|
2022-08-19 |
2024-04-25 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|